Unternehmensübersicht
Apellis Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of novel therapeutic compounds designed to address diseases characterized by significant unmet medical needs. The company functions within the Healthcare sector and specifically within the Biotechnology industry, positioning itself to leverage specialized scientific expertise in targeted drug therapies. Its current scale is defined by a market capitalization of $2.17 billion, an annual revenue of $1.00 billion, and an employee base of 733 individuals. These valuation and revenue figures indicate that Apellis occupies a mid-to-large cap position within the biotechnology landscape, possessing substantial resources for R&D while maintaining a revenue stream sufficient to support its operational infrastructure and ongoing clinical programs.
Finanzielle Gesundheit
The company reported a trailing twelve-month revenue of $1.00 billion and a net income of $22.39 million, resulting in an EBITDA of $56.98 million. The substantial gap between the $1.00 billion revenue and the $22.39 million net income reveals a cost structure where significant operating expenses, likely driven by research and development and commercialization costs, absorb a large portion of gross revenue before reaching the bottom line. Free cash flow stands at $-15,464,500, indicating a net cash outflow from operations after capital expenditures, which suggests the company is prioritizing reinvestment in its pipeline over immediate cash retention. Analyzing the margins shows a gross margin of 60.3%, reflecting the high value added by the manufacturing and sale of its pharmaceutical products relative to the cost of goods sold. However, the operating margin of -25.6% and a profit margin of 2.2% highlight that general and administrative costs, along with R&D expenditures, are currently exceeding operating revenue on a pre-tax basis. The balance sheet presents a leveraged profile with cash holdings of $467.79 million against total debt of $474.36 million, yielding a debt-to-equity ratio of 128.15. Despite the near parity between cash and debt, the high debt-to-equity ratio indicates that the company relies heavily on borrowed funds relative to shareholder equity. Liquidity is robust, evidenced by a current ratio of 3.14, which signifies that the company holds more than three times the current assets necessary to cover its short-term liabilities. Return on equity is recorded at 7.5% and return on assets at 3.5%, metrics that reveal management's effectiveness in generating returns on the capital invested, though the ROA remains modest relative to the high leverage.
Bewertungsanalyse
The valuation metrics display a trailing P/E ratio of 94.28 and a forward P/E of -66.29, implying that expected earnings are currently negative in the near term, which drives the forward multiple into negative territory and suggests a divergence from historical profitability. The price-to-book ratio stands at 5.81, indicating that the market values the company at nearly six times its book value, reflecting a significant market premium assigned to its intellectual property and future growth potential rather than its current tangible asset base. Alternative valuation metrics include a price-to-sales ratio of 2.16 and an EV/EBITDA of 38.18, which suggest the market is pricing the stock based on revenue growth prospects and enterprise value relative to earnings power despite current losses. The stock price has fluctuated between a 52-week low of $16.10 and a 52-week high of $30.48, establishing a trading range that captures the volatility typical of biotechnology equities. The beta value is 0.29, which indicates that the stock's price volatility is significantly lower than that of the broader market, suggesting less sensitivity to general market movements compared to larger-cap peers.
Growth & Income
Revenue growth year-over-year is recorded at -5.9%, while earnings growth is listed as N/A due to the current lack of profitability. The decline in revenue suggests a contraction in sales or market share, and since the company is not generating positive earnings growth, the implication is that the business is still in a phase of scaling or restructuring rather than expanding profitably. As a non-dividend payer, the company does not distribute a dividend yield or maintains a payout ratio of 0.0%, meaning all available earnings are retained and reinvested directly into growth initiatives such as drug development and clinical trials rather than being returned to shareholders. The overall growth and income profile characterizes Apellis as a capital-intensive growth stock that forgoes current income distribution to fund future therapeutic advancements, operating without a dividend safety net while navigating a period of revenue contraction.